Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus
Healthcare systems now have clear guidelines for when and how to test for a genetic change that makes certain breast cancers treatable.
A multidisciplinary Italian expert panel achieved consensus on PIK3CA molecular testing standards for advanced HR+/HER2- breast cancer patients eligible for alpelisib or inavolisib, covering preanalytical, analytical, and clinical decision-making domains. This document provides operational guidance to harmonize testing practice across institutions for a major and growing treatment-actionable genomic alteration.
What the study was
- Study design
- Structured multidisciplinary expert consensus (16 Italian oncology experts, 29 statements, 23/29 reached 100% agreement)
- Population
- Patients with advanced HR+/HER2- breast cancer eligible for PIK3CA-targeted therapy (alpelisib, inavolisib)
- Category
- Genomics/Precision Medicine
- Maturity
- Potentially Practice-Changing
- Journal
- Breast
Why it surfaced
Practice-level consensus from a major oncology center network; PIK3CA testing affects ~40% of HR+/HER2- BC patients and determines eligibility for approved targeted agents; standardized guidance directly improves clinical workflows.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.